Unresectable or metastatic melanoma with a BRAF V600 mutation (inoperable stage III or metastatic stage IV) research hub

Surgical or radiotherapeutic intervention concerning large singular stable to progressive metastases in patients with BRAFV600-mutated melanoma receiving treatment with Encorafenib + Binimetinib

This study looks at how well different treatments like surgery or radiotherapy work for people with a specific type of advanced melanoma. They are already taking two medicines, Encorafenib and Binimetinib, and researchers want to see if adding these other treatments helps them live longer without their cancer growing.